Site-specific bioconjugation of engineered antibodies Advances in bioorthogonal chemistry and protein engineering have contributed to the production of more uniform ADC. Although there are many attachment methods available for natural McAbs, site-specificRead More…
Chemical modification of specific in situ antibody The natural structure of monoclonal antibodies provides a variety of possibilities for bioconjugation. The chemical-based, specific natural (non-engineered) antibody conjugation has some benefits in thatRead More…
The linker is not only the molecular part of the covalent connection between the antibody and the small molecular payload but also a key element with design properties in targeted drug therapy.Read More…
Creative Biolabs, one of the industry-pioneering CROs holding specialties in bioconjugate, participated in the 13th Annual World ADC Summit last week and announced the successful accomplishment of its journey in San Diego.Read More…
Innovative Drugs Apoptosis inducer (Bcl-xL inhibitor) The overexpression of anti-apoptotic Bcl-2 family members (including Bcl-xL) is one of the mechanisms by which cancer cells acquire apoptosis resistance. Drugs that block the BH3-bindingRead More…
DNA-damaging Drugs Pyrrolobenzodiazepine and Indolinobenzodiazepine Pyrrolobenzodiazepines (PBD) is a kind of natural product with antineoplastic activity. Their mode of action is selective alkylation in a small groove of DNA, in which guanineRead More…
Antibody-drug conjugate (ADC) is formed by linking monoclonal antibodies targeting specific antigens with small molecular cytotoxic drugs through linkers, which have both the strong killing effect of traditional small molecule chemotherapy andRead More…
Breast cancer is the most common cancer among women. In 2020, breast cancer has replaced lung cancer as the number one cancer in the world. The latest global cancer burden data forRead More…
With the approval of a number of ADC drugs around the world since 2019, conjugated drugs have developed into one of the hottest tracks in the pharmaceutical industry. Not only traditional ADCRead More…
An ADC consists of an antibody and toxin bridged by a linker that affects the coupling stability to some extent and has an important influence on ADC efficacy. The premature release ofRead More…